Pharmaceutical Industry and Idiosyncratic Risk
Main Article Content
Abstract
The study tries to develop a model that contains variables that can be used to determine both the market risk and the idiosyncratic risk unique to the
pharmaceutical industry, which is characterized as a capital intensive industry and mainly deals with producing products that are considered long-term investment. The results suggest that significant determinants for the market risk are size, leverage, and efficiency when capital is excluded and size, capital, and efficiency when leverage is excluded. The significance and the signs o f the regression coefficients imply that market investors consider that the larger the size of the pharmaceutical company the lower is the market risk and have higher the leverage or debt ratio the larger is the market risk and V finally higher is the efficiency of the company the lower is the market risk. Further the results indicate that the significant determinants of idiosyncratic risk are size and earnings variability whether leverage or capital is included in the determinants set. These two significant determinants provide increased guidance to investors seeking diversification to minimize specific risk.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
[1 ] Cambell John Y„ Martin Lettau, Burton G. Malkiel, and YexiaoXu 2000. “Have Individual Stocks Become More Volatile?" Journal of Finance.
[2] Gongola, 2003, “Prescriptions for Change: The Hatch-Waxman Act and New Legislation to Increase the Availability of Generic Drugs Consumers”, 36 Indiana Law Review 78 7.
[31 Paine, 2003, “Brand-Name Drug Manufacturers Risk Antitrust Violations by Slowing Generic Production Through Patent Layering", 33 Sett Hall Law Review 479.
[4] Piatt, 2003, “Regaining the Balance o f Hatch-Waxman in the FDA Approval Process: An Equitable Remedy to the Thirty-Month Stay”, 59 New York University Annual Survey of American Law 163.
[5] Robinson, 2003, “Recent Administrative Reforms of the Hatch-Waxman Act: Lower Prices Now in Exchange for Less Pharmaceutical InnovatuLater?”81 Washington University Law Quarterly829.
[6] Soehnge,2003, “The Drug Price Competition and Patent Term Expiration Act o f1984: Fine-Tuning the Balance Between the Interests of Pione and Generic Drug Manufacturers.” 58 Food and Drug Law Institute Law Journal 51.
[7] Urevig, 2003, “Hatch-Waxrnan Thoughtful Planning or Just Piling On: A Consideration o f the Federal Trade Commission's Proposed Changes”, 4 Minnesota Intellectual Property> Review 367.